Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 2Active not recruiting 2Withdrawn 1Not yet recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 5Squamous Cell Carcinoma of Head and Neck 3Uterine Cervical Neoplasms 2Nasopharyngeal Carcinoma 2Stomach Neoplasms 1Pancreatic Cancer Resectable 1Oropharyngeal Neoplasms 1Mouth Neoplasms 1Locally Advanced Gastric Cancer 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1Esophageal Squamous Cell Carcinoma 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1Breast Neoplasms 1Adenocarcinoma Of Esophagus 1

Interventions

toripalimab 6Cisplatin 5130-nm albumin-bound paclitaxel 5Drug Therapy 4tislelizumab 3sintilimab 3camrelizumab 3Injections 3Immune Checkpoint Inhibitors 3Fluorouracil 3Carboplatin 3nedaplatin 2anlotinib 2Radiotherapy 2Paclitaxel 2Neoadjuvant Therapy 2Irinotecan 2Esophagectomy 2potassium oxonate 1pembrolizumab 1lenvatinib 1ivarmacitinib 1irinotecan sucrosofate 1Watchful Waiting 1Taxes 1TP protocol 1S 1 (combination) 1Radiotherapy, Intensity-Modulated 1Radiation 1Observation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Esophageal Squamous Cell Carcinoma × Taxes × Clear all
NCT07618910 2026-06-01

Retlirafusp Alfa Plus Chemotherapy as Neoadjuvant Therapy for Thoracic ESCC

Tang-Du Hospital

Phase 2 Not yet recruiting
33 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡